SLAM
MRNA icon

Swiss Life Asset Management’s Moderna MRNA Stock Holding History

Swiss Life Asset Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.76M Sell
25,088
-573
-2% -$29.6K 0.01% 603
2026
Q1 		$1.3M Buy
25,661
+7,150
+39% +$334K 0.01% 610
2025
Q4 		$546K Sell
18,511
-3,047
-14% -$82.8K ﹤0.01% 766
2025
Q3 		$557K Buy
21,558
+5,523
+34% +$154K ﹤0.01% 693
2025
Q2 		$442K Sell
16,035
-9,531
-37% -$251K ﹤0.01% 676
2025
Q1 		$725K Buy
25,566
+4,415
+21% +$157K 0.01% 642
2024
Q4 		$878K Buy
21,151
+5,689
+37% +$272K 0.01% 605
2024
Q3 		$1.03M Sell
15,462
-2,870
-16% -$264K 0.01% 456
2024
Q2 		$2.18M Buy
18,332
+4,779
+35% +$605K 0.03% 362
2024
Q1 		$1.44M Sell
13,553
-38,160
-74% -$3.85M 0.02% 383
2023
Q4 		$5.15M Buy
51,713
+22,127
+75% +$1.86M 0.06% 317
2023
Q3 		$3.06M Sell
29,586
-8,721
-23% -$973K 0.05% 378
2023
Q2 		$4.65M Sell
38,307
-4,749
-11% -$634K 0.07% 321
2023
Q1 		$6.61M Buy
43,056
+11,558
+37% +$1.91M 0.1% 259
2022
Q4 		$5.66M Sell
31,498
-5,018
-14% -$820K 0.09% 248
2022
Q3 		$4.32M Sell
36,516
-594
-2% -$90.1K 0.07% 286
2022
Q2 		$5.3M Sell
37,110
-8,470
-19% -$1.21M 0.09% 257
2022
Q1 		$7.85M Sell
45,580
-11,009
-19% -$1.85M 0.11% 205
2021
Q4 		$14.4M Buy
56,589
+9,286
+20% +$2.72M 0.19% 120
2021
Q3 		$18.2M Buy
47,303
+33,335
+239% +$12.3M 0.25% 89
2021
Q2 		$3.88M Buy
13,968
+5,731
+70% +$1.02M 0.04% 364
2021
Q1 		$1.08M Buy
+8,237
New +$1.19M 0.02% 442

Other funds holding MRNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Swiss Life Asset Management's MRNA Position: Q2 2026 in Review

Swiss Life Asset Management reduced its Moderna (MRNA) stake by 2.2% in Q2 2026, selling an estimated $29.6K and leaving 25,088 shares worth $1.76M. The position accounts for 0.01% of the portfolio, ranked #603.

Swiss Life Asset Management first reported a position in MRNA in Q1 2021 and has held it in 22 quarters since. The position peaked at $18.2M in Q3 2021. 614 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Swiss Life Asset Management held 25,088 shares of Moderna worth $1.76M as of Q2 2026.
  • Swiss Life Asset Management sold 573 Moderna shares in Q2 2026, an estimated $29.6K.
  • Moderna made up 0.01% of Swiss Life Asset Management's portfolio in Q2 2026, its #603 holding.
  • Swiss Life Asset Management first reported a position in Moderna in Q1 2021 and has held it in 22 quarters since.
  • Swiss Life Asset Management's Moderna position peaked at $18.2M in Q3 2021.
  • 614 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.